Publications
CER Interview with Barbara McLaughlan
| Type: | Podcast |
| Date: | January 6, 2012 |
| Related Topics: | Aging Research, Drug Development, Drug Safety, Medical Innovation, Policy, Research, Vision Loss |
Barbara McLaughlan is the Policy & Campaigns Manager at the Royal National Institute of Blind People(RNIB). At RNIB, McLaughlan has played a major role in the successful campaign to ensure that patients with wet age-related macular degeneration are given treatment with new anti-VEGF treatments on the NHS. Access to treatment remains a major focus of her work as well as running several eye health promotion projects. Ms. McLaughlan is also the Chair of Patients involved in NICE (PIN), an independent group made up of patient and voluntary organizations that work closely with NICE.
Tweet
"From a patient’s perspective, if I were the patient I would always say ‘I want the licensed treatment because that’s gone through all the trials and I can be absolutely sure about what I’m getting, plus there is monitoring of outcomes and possible adverse events following licensing and use in clinical practice.”
Tweet
This podcast series provides expert reactions to the CATT trial data in terms of what it will mean for wAMD patients and professionals, and its potential impact on future trials, policies and innovation.
To listen to interviews on this topic with other experts, click here.
To listen to interviews on this topic with other experts, click here.
Living Longer and Loving It!
Sign up for the Alliance's quarterly newsletter and get timely information on advancements in science, treatment, and health policy that help you "Live Longer and Love It."